Results 171 to 180 of about 2,706,111 (311)

PTEN restrains SHH medulloblastoma growth through cell autonomous and nonautonomous mechanisms. [PDF]

Elife
Lao Z, El Nagar S, Liang Y, Stephen D, Joyner AL.   +4 more
europepmc   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Malignant Melanoma Bone Metastasis With Unknown Primary Site: A Case Report and Literature Review

Case Reports in Orthopedics
Cao Wang, Yan Liu, Lei Han, Xin Qu, Hang Yang, Fengming Ran, Dongqi Li, Dachang Xu, Chenying Yang, Zuozhang Yang   +9 more
doaj   +1 more source

Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence. [PDF]

BMC Cancer
Beck MH, Kordowitzki P, Roser E, Trelinska-Finger A, Schoof E, Chinczewski L, Mechsner S, Sehouli J.   +7 more
europepmc   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations. [PDF]

Cancer Immunol Immunother
Fatahichegeni M, Ansarian MA, Xiao M, Gao W, Shi R.   +4 more
europepmc   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Educational Case: Meningioma. [PDF]

Acad Pathol
Carter AM, Dai H, Klause H, Musto A, Conran RM.   +4 more
europepmc   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer. [PDF]

Sci Rep
Yang L, Bhattacharya A, Li Y, Peterson D, Zhang Y.   +4 more
europepmc   +1 more source